Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Nemonoxacin in Severe Renal Impairment
NCT02840812Phase 1Unknown
- Sponsor
- Zhejiang Medicine Co., Ltd.
- Start
- Apr 2017
- Primary completion
- Jan 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of nemonoxacin in community acquired pneumonia (CAP) (2 arms), sponsored by Zhejiang Medicine Co., Ltd. Primary endpoints: Maximum Plasma Concentration at 72 hours, Time to Maximum Concentration at 72 hours and 8 more. Status: unknown.
02
Drugs
nemonoxacin
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT02840812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02840812.